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Abstract Double reading may be a valuable tool for improv-
ing the quality of patient care by restoring diagnostic errors
before final sign-out, but standard double reading would sig-
nificantly increase costs of pathology. The aim of this study
was to assess the added value of routine double reading of
defined categories of clinical cytology specimens by special-
ized cytopathologists. Specialized cytopathologists routinely
re-diagnosed blinded defined categories of clinical cytology
specimens that had been signed out by routine pathologists
from January 2012 up to December 2013. Major and minor
discordance rates between initial and expert diagnoses were
determined, and both diagnoses were validated by comparison
with same-site histological follow-up. Initial and expert diag-
noses were concordant in 131/218 specimens (60.1 %). Major
and minor discordances were present in 28 (12.8 %) and 59
(27.1 %) specimens, respectively. Pleural fluid, thyroid and
urine specimens showed the highest major discordance rates
(19.4, 19.2 and 16.7 %, respectively). Histological follow-up
(where possible) supported the expert diagnosis in 95.5 % of
specimens. Our implemented double reading strategy of de-
fined categories of cytology specimens showed major discor-
dance in 12.8 % of specimens. The expert diagnosis was sup-
ported in 95.5 % of discordant cases where histological
follow-up was available. This indicates that this double read-
ing strategy is worthwhile and contributes to better
cytodiagnostics and quality of patient care, especially for sus-
picious pleural fluid, thyroid and urine specimens. Our results
emphasize that cytopathology is a subspecialization of pathol-
ogy and requires specialized cytopathologists.
Keywords Cytopathology . Diagnostic accuracy . Patient
safety . Quality assurance . Subspecialization
Introduction
There is a growing awareness that pathology diagnosis is not
infallible and that diagnostic errors may lead to under- or
overtreatment and thereby compromise patient safety. Double
reading is a potentially valuable tool for reducing diagnostic
errors and thereby improving the quality of patient care. It
may reveal inaccurate diagnoses that otherwise might have
led to improper or unnecessary patient management or treat-
ment. In response to the Institute of Medicine report ‘To err is
human; building a safer health system’ from 1999 [1], the
American Society for Clinical Pathology (ASCP) recognized
second opinion as a key aspect in the assurance of patient
safety for histological and cytological diagnoses [2]. They
recommended to consider second opinion in several situa-
tions, including highly critical or significant cases, problem-
prone cases and cases suggested for review by clinicians [2].
Many studies focused on second opinion in diagnostic sur-
gical pathology and reported major diagnostic disagreement
rates of 2 to 28 %, mainly depending on the organ system
studied [3–24]. A smaller number of studies focused on sec-
ond opinion in cytopathology, of which the majority reported
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disagreement rates of specific organs or organ systems, pre-
dominantly the thyroid [25–31]. Few studies, however,
assessed the impact of double reading on patient care for the
whole subset of cytological specimens. These studies reported
major disagreement rates ranging from 7.4 to 9.3 % [32–34],
and second opinion diagnoses were better supported by histo-
logical follow-up than the initial diagnoses [32, 33].
Therefore, we implemented intradepartmental double read-
ing by expert cytopathologists on January 1, 2012. Since rou-
tine double reading of all specimens would significantly in-
crease costs, we predefined selected categories of cytology
cases where the yield of double reading was expected to be
highest. In this study, we assessed the added value of this
expert double reading strategy. To this end, we retrospectively
determined the rates of concordance and major and minor
discordance between initial and second opinion diagnoses of
all cytology cases reviewed by the expert cytopathologists.
Furthermore, we validated both diagnoses by comparisonwith
same-site histological follow-up.
Materials and methods
Routine intradepartmental second review
Figure 1 demonstrates the routine cytology diagnostics pro-
cess at Symbiant’s three pathology laboratories (Alkmaar
Medical Centre, Westfriesgasthuis Hoorn and Zaandam Med-
ical Centre). All cytological specimens were routinely
prescreened for abnormalities by one or two cytotechnicians.
Subsequently, the prescreened specimens are examined by
either a general pathologist (in the Alkmaar and Hoorn labo-
ratories) or both general pathologists and expert
cytopathologists in the Zaandam laboratory.
Starting from January 1, 2012, a cytopathology expert team
in the Zaandam laboratory began reviewing defined categories
of clinical cytology specimens from the Alkmaar and Hoorn
pathology laboratories, resulting in a consensus diagnosis.
The team consisted of two expert cytopathologists (DSG and
MV). A second review was performed blinded to the initial
diagnoses. The following types of specimens were routinely
sent for intradepartmental second review: difficult or suspi-
cious cases and cases with a discrepancy between the general
pathologists’ diagnoses, with the clinical presentation or with
immunohistochemical stains.
The cytopathologists were either consulted before case
sign-out, when the initial pathologist was unable to offer a
preliminary diagnosis, or asked for a second opinion after
preliminary sign-out. For the purpose of this study, the cases
where the expert cytopathologists were consulted pre-sign-out
were excluded from analysis. In the remaining cases, the ini-
tial diagnoses and the expert diagnoses were recorded and
compared.
Assessment of concordance between initial and expert
diagnoses
We thereby retrospectively assessed all clinical cytopathology
cases of 2012 and 2013 that had been reviewed by the expert
cytopathologists and determined concordance between initial
and expert diagnoses. We applied the same definitions for
minor and major discordances as described by Lueck et al.
and Bomeisl et al. [32, 33]. Minor discordance was defined
as a 1-step deviation on the scale of ‘non-diagnostic, benign,
atypical, suspicious and malignant’ without an effect on treat-
ment or prognosis. Major discordance was defined as either a
deviation of ≥2 steps on this scale or a discordance with effect
on patient management or prognosis.
Validation of diagnoses by comparison with histological
follow-up
We validated initial and expert diagnoses by comparison with
same-site histological follow-up diagnoses. The process of
follow-up identification is explained in the following section.
The diagnosis closest to the follow-up diagnosis was deemed
correct. Non-diagnostic specimens, which had insufficient di-
agnostic material or were non-representative, were not vali-
dated by histological follow-up.
Identification of cytohistologically discordant cases
As follow-up identification is a very time-consuming activity,
a cytotechnician at Symbiant (HdL) developed the follow-up
tool Follow Up application SYMbiant (FUSYM), which pro-
vides histological follow-up for cytology specimens by auto-
mating several steps in the process. FUSYM has been devel-
oped in Microsoft Visual Studio 2010 professional and was
written in Microsoft Visual Basic.
The Netherlands employs a unique system whereby all
reports from the Dutch pathology laboratories are stored in a
central database (PALGA) via a local server. All histological
examinations subsequent to the cytological examination were
routinely extracted from PALGA and loaded into FUSYM.
The following was coded while loading data: tissue type, or-
gan, sampling region, sampling method and side. Further-
more, diagnoses were classified at three levels, known as di-
agnostic group (unknown, non-diagnostic, benign, atypia or
malignant), main diagnosis (benign was subdivided into no
abnormalities, benign lesion and benign neoplasm, and malig-
nant was subdivided into suspicious and malignant neoplasm)
and specific diagnosis. Subsequently, the actual follow-up ex-
amination from the same site as the cytology specimen (i.e.
same organ and sampling region) was determined manually
for every cytology specimen.
Finally, cytology and histology follow-up diagnoses were
compared at the level of diagnostic group to determine the
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cytohistologic concordance rate and the number of ‘false-neg-
ative’ and ‘false-positive’ cytology diagnoses. Suspicious as
well as malignant cytology diagnoses with a malignant histo-
logical follow-up were deemed concordant. Non-diagnostic
cytology or histology specimens or specimens with a diagno-
sis of atypia were excluded from analysis.
Retrospective double reading of a sample
of cytohistologically discordant cases initially not undergoing
double reading
To assess the quality of cytodiagnostics of the cases from 2012
to 2013 that did not undergo routine double reading,
Fig. 1 The routine cytology
diagnostics process at Symbiant’s
three pathology laboratories. Lab
AAlkmaar Medical Centre, Lab B
Westfriesgasthuis Hoorn, Lab C
Zaandam Medical Centre
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concordance with histological follow-up was determined. Of
the cytohistologically discordant cases, we randomly selected
a sample of 100 specimens from the Alkmaar pathology lab-
oratory to be retrospectively reviewed by the expert
cytopathologists, blinded to the original diagnosis, and record-
ed whether the expert diagnosis was concordant or discordant
with the initial diagnosis. A discordant diagnosis was
subdivided into (1) a change from benign to malignant, or vice
versa, resulting in expert cytohistologic concordance; (2) a
change from benign or malignant into atypia; or (3) a change
into non-diagnostic.
Statistics
Statistical analysis was performed using SPSS 20. Initial
diagnoses and expert diagnoses were compared using the
unweighted Cohen’s kappa (K) coefficient. A K value of
0.00–0.20 indicates a slight agreement, 0.21–0.40 a fair
agreement, 0.41–0.60 a moderate agreement, 0.61–0.80 a
substantial agreement and 0.81–1 a perfect agreement.
Furthermore, the percentages of concordance and discor-
dance with their 95 % confidence intervals (CI) were
calculated. P values <0.05 were considered statistically
significant.
Results
Specimens routinely undergoing double reading
During the study period, 296 clinical cytology specimens
underwent rout ine double reading by the expert
cytopathologists. We excluded 78 cases where the initial di-
agnoses were not recorded, because pathologists consulted the
expert team before case sign-out, leaving 218 specimens.
From 12 patients, multiple cytology specimens were included
as separate cases (11 patients with 2 specimens and 1 patient
with 3 specimens). Table 1 summarizes the tissue types and
sampling methods of the 218 specimens.
Both diagnoses were concordant in 131 specimens
(60.1 %; 95 % CI 0.535–0.666, kappa 0.489, P<0.0001).
Major discordance between the initial and the expert diagno-
ses was seen in 28 specimens (12.8 %; 95 % CI 0.084–0.173)
and minor discordance in 59 specimens (27.1 %; 95 % CI
0.211–0.330). Table 2 summarizes the types of major and
minor discordances. Of all discordant specimens, the initial
diagnosis was underestimated 45 times (51.7 %) and
overestimated 37 times (42.5 %). Twice, a benign diagnosis
was changed into non-diagnostic, and 1 specimen was
changed from non-diagnostic into malignant. Furthermore,
for 1 specimen, an unspecific benign diagnosis (no malignan-
cy) was specified into aWarthin tumour, and in another case, a
diagnosis of metastatic squamous cell carcinoma was changed
into metastatic adenocarcinoma.
Table 3 shows the frequencies of discordant second opinion
diagnoses subdivided by the eight tissue types with ≥10 spec-
imens reviewed by the expert cytopathologists. Pleural fluid,
urine and bile duct brush specimens showed the highest over-
all discordance rates (58.1, 50.0 and 46.2 %, respectively).
Major discordances were most commonly observed in pleural
fluid, thyroid and urine specimens with 19.4, 19.2 and 16.7%,
respectively. Minor discordances were most commonly ob-
served in bile duct brush, pleural fluid and bronchial speci-
mens with 46.2, 38.7 and 36.4 %, respectively. Breast cytolo-
gy specimens showed the lowest discordance rate, with one
minor discordant expert diagnosis (9.1 %). The total major
and minor discordance percentages of this subset of speci-
mens (tissue types with ≥10 specimens) were similar to those
of the whole study selection (all tissue types).
Validation by comparison with histological follow-up
Same-site histological follow-up was available for 25 of the
87 discordant specimens, but was non-diagnostic for 3 speci-
mens. Hence, we validated the initial and expert diagnoses of
22 cytology specimens by comparison with histological fol-
low-up. The expert diagnosis was supported by the histology
diagnosis in 21/22 specimens (95.5 %; 95%CI 0.860–1.049).
Table 1 Summary of tissue types and acquisition methods of 218
clinical cytology specimens undergoing double reading by expert
cytopathologists
Tissue type Number Percentage
Thyroid FNA 52 23.9
Lymph node FNA 40 18.3
Pleural fluid 31 14.2
Salivary gland FNA 22 10.1
Bile duct brush 13 6.0
Urine 12 5.5
Bronchial FNA/brush/lavage 11 5.0
Breast FNA/nipple discharge 11 5.0
Ascitic fluid 8 3.7
Adrenal gland FNA 6 2.8
Liver FNA/brush 3 1.4
Pancreas FNA 2 0.9
Pericardial fluid 2 0.9
Cerebrospinal fluid 1 0.5
Peritoneal FNA 1 0.5
Esophageal FNA 1 0.5
Scrotal FNA 1 0.5
Retro-auricular FNA 1 0.5
FNA fine needle aspiration
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The case that was not supported by histology revealed a ma-
lignant mesothelioma, which was not diagnosed in the pleural
fluid cytology by both the initial pathologist as well as the
expert cytopathologist.
Retrospective second review of cytohistologically discordant
cases
In order to get an impression of the quality of cytology diag-
nostics in those specimens that did not undergo double read-
ing in routine diagnostics, we determined the rates of concor-
dance and discordance with histological follow-up in these
specimens. Same-site histological follow-up was available
for 1613 cases, of which we excluded 338 cases, because
either cytology, histology or both were non-diagnostic or
had a diagnosis of atypia. Furthermore, we excluded 24 cases
with a time period between cytological and histological exam-
ination longer than 6 months and 17 cases with only a few
malignant cells on histology, leaving 1234 cases.
Cytohistological concordance was found for 943 cytology
specimens (76.4 %; 95 % CI 0.740–0.788), and 291 cytology
specimens (23.6 %) had a discordant histological follow-up.
For the random sample of 100 cytohistologically discor-
dant cases from the Alkmaar pathology laboratory, the expert
diagnosis was consistent with the initial diagnosis in 57 %
(95 % CI 0.471–0.669). The cytopathologists changed the
diagnosis in 43 % of cases: in 17 cases, the diagnosis was
changed from benign to malignant (10 cases) or vice versa
(7 cases), resulting in cytohistological concordance; a benign
or malignant diagnosis was changed into atypia in 8 cases, and
a diagnosis was changed into non-diagnostic 18 times.
Discussion
This study assessed the added value of our implemented
intradepartmental double reading strategy of defined catego-
ries of clinical cytology specimens by a team of expert
cytopathologists. We demonstrated a 60.1 % concordance
rate, a 12.8 % major discordance rate and a 27.1 % minor
discordance rate between initial and expert diagnoses. The
highest major discordance rates were observed in pleural fluid,
thyroid and urine specimens. Validation by comparison with
same-site histological follow-up confirmed that expert diag-
noses were correct in 95.5 % (95 % CI 0.860–1.049). These
findings emphasize the importance of double reading of se-
lected specimens by expert cytopathologists.
Previous studies on cytopathology double reading demon-
strated somewhat lower major discordance rates (7.4 to 9.3 %)
[32–34], probably due to differences in specimen selection. At
Table 2 Types of major
discordances (n=28) and minor
discordances (n=59) for clinical
cytology specimens undergoing
double reading by expert
cytopathologists
Type of major discordance Number Percentage Type of minor discordance Number Percentage
Underestimated 14 50.0 Underestimated 31 52.6
Benign→suspicious 4 14.3 Benign→atypia 1 1.7
Benign→malignant 3 10.7 Atypia→suspicious 7 11.9
Atypia→malignant 7 25.0 Suspicious→malignant 23 39.0
Overestimated 13 46.4 Overestimated 24 40.7
Malignant→atypia 1 3.6 Malignant→suspicious 2 3.4
Malignant→benign 2 7.1 Suspicious→atypia 7 11.9
Suspicious→benign 10 35.7 Atypia→benign 15 25.4
Other 1 3.6 Other 4 6.8
Table 3 Frequencies of
discordances subdivided by tissue
type
Tissue types with ≥10 cytology
specimens reviewed by the expert
cytopathologists were compared
FNA fine needle aspiration








Pleural fluid 31 18 (58.1 %) 6 (19.4 %) 12 (38.7 %)
Urine 12 6 (50.0 %) 2 (16.7 %) 4 (33.3 %)
Bile duct brush 13 6 (46.2 %) – 6 (46.2 %)
Bronchial FNA/brush/lavage 11 5 (45.5 %) 1 (9.1 %) 4 (36.4 %)
Thyroid FNA 52 23 (44.2 %) 10 (19.2 %) 13 (25.0 %)
Lymph node FNA 40 11 (27.5 %) 6 (15.0 %) 5 (12.5 %)
Salivary gland FNA 22 6 (27.3 %) – 6 (27.3 %)
Breast FNA/nipple discharge 11 1 (9.1 %) – 1 (9.1 %)
Total 192 76 (39.6 %) 25 (13.0 %) 51 (26.6 %)
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our institution, defined categories of clinical cytology speci-
mens were reviewed, whereas others described second review
of all referred cytopathology material before definitive treat-
ment. Furthermore, we specifically assessed the added value
of double reading by expert cytopathologists. In these studies
as well, high major disagreement rates of thyroid FNA spec-
imens were observed (16.2 to 24.3 %), and in the study of
Lueck et al. [32], major discrepancies in urine specimens were
the third most common (16.2 %).
The high discordance rates in urine and pleural fluid speci-
mens might be partly explained by the lack of standard termi-
nology and the use of inadequate terms, especially for atypical
lesions [35]. Implementation of the Paris System for Urinary
Cytopathology, which is currently being developed, might im-
prove urine cytology diagnostics [36]. This explanation does,
however, not hold true for thyroid cytology specimens, because
of well-defined terminology in the Bethesda System for
Reporting Thyroid Cytopathology (BSRTC) [37].We therefore
suppose that most discrepancies were a result of inadequate
interpretation instead of inadequate terms used. The majority
of thyroid cytology discrepancies were caused by initial over-
estimation of benign and atypical specimens.
Initial underestimation occurred in slightly more discordant
cytology specimens than overestimation did (51.7 and 42.5 %,
respectively). This difference mainly represented minor discor-
dant specimens, of which malignancies being underestimated
as suspicious were most commonly observed, indicating reluc-
tance among general pathologists to label cases as malignant.
Among the major discordant specimens, the proportions of
underestimated and overestimated diagnoses by general pathol-
ogists were evenly distributed.
A limitation of this study is the relatively small availability
of same-site histological follow-up (in 25/87 discordant speci-
mens) to validate expert diagnoses, which may lead to partial
verification bias. Reasons for the absence of same-site histo-
logical follow-up were assessed. They included the presence of
a benign cytology or benign follow-up cytology diagnosis (n=
18), the presence of histological follow-up obtained from an-
other related site (n=10) or radiological follow-up (n=3). For
17 patients, histological follow-up would have been superflu-
ous, because they already suffered from incurable metastatic
malignancies. Furthermore, 12 patients were treated in an aca-
demic hospital or another local hospital, of which patient charts
were unavailable to us, and 1 patient died very shortly after
cytological examination. Finally, for 1 patient with an atypical
thyroid cytology specimen, an intended hemithyroidectomy
was probably cancelled for an, to us, unknown reason.
Our double reading strategy reveals major discordant diag-
noses in a substantial number of cytology cases. Although
standard double reading of all cytology specimens would be
ideal in terms of patient safety, it would significantly increase
workload and costs of pathology. Alternatively, all cytology
could be signed out by expert cytopathologists, but this is in
general pathology practice difficult to realize. In line with the
present results, Raab et al. [38] demonstrated that focused re-
view of diagnostically challenging areas of surgical pathology
was more time- and cost-effective than 5 % random review and
detected a significantly higher frequency of discrepancies. In
order to get an impression of the quality of cytology diagnostics
in those specimens that did not undergo double reading in
routine diagnostics, we determined the concordance rate with
histological follow-up, which appeared to be 76.4 %. Retro-
spective double reading of a random sample of 100
cytohistologically discordant specimens changed the diagnosis
in 43 cases, with urine and lymph node specimens most com-
monly adapted. In these cases, the sign-out pathologist proba-
bly had been sufficiently confident of the diagnosis and there-
fore had not consulted the expert cytopathologists. This argues
for investigating which further specimen types are problematic
as well and would probably also benefit from initial double
reading, in order to refine the double reading strategy.
Patient safety is of utmost importance, and, in our opinion,
cytopathology is a subspecialization of pathology that requires
specialized cytopathologists, because the discordance rates are
unacceptably high. The Dutch thyroid carcinoma guideline
[39] states that ‘thyroid FNAs should be assessed by a pathol-
ogist with interest and experience in thyroid cytology and
histology, who can recommend management or treatment
based on the cytology results. If an experienced pathologist
is not available locally, the sample should be sent to a pathol-
ogist that does have expertise in this field.’ Also, the Dutch
bladder carcinoma guideline [40] states that ‘reliability of
urine cytology evaluation is dependent on the expertise of
the (cyto)pathologist.’ The Board of Pathology of the Europe-
an Union of Medical Specialists (UEMS) published require-
ments for recognition of postgraduate training in pathology
and stated that cytopathology is an integral part of pathology
and well-trained pathologists must be able to cover basic cy-
tological diagnosis [41]. Pathologists can obtain post-graduate
‘advanced level of competence’ certificates in cytopathology
[41]. We agree with Anshu et al. [42] who stated that ‘Euro-
pean and international guidelines for training and accredita-
tion in cytopathology should be developed with some urgen-
cy’. Guidelines should include an annual minimum number of
specimens that a (cyto)pathologist must view and recommen-
dations for further education and examination.
Conclusion
Our implemented double reading strategy of defined categories
of cytology specimens showed major discordance in 12.8 % of
specimens. The expert review was supported in 95.5 % of
discordant cases where histological follow-up was available.
This indicates that this double reading strategy is worthwhile
and contributes to better cytodiagnostics and quality of patient
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care, especially for suspicious pleural fluid, thyroid and urine
specimens. Although it is currently not reimbursed and formal
cost-effectiveness studies are lacking, we believe that selected
second review may prevent overtreatment of a subgroup of
patients in a cost-effective way and, also in the light of the
upcoming claim culture in Europe, should therefore be consid-
ered for regular reimbursement. Our results emphasize that
cytopathology is a subspecialization of pathology and requires
specialized cytopathologists.
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